What NRX Pharmaceuticals, Inc. does.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”, the “Company”, “we”, “us” or “our”) is a clinical-stage bio-pharmaceutical company which develops and will distribute, through its wholly-owned operating subsidiary, NeuroRx, Inc., (NeuroRx), novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, post-traumatic stress disorder (PTSD) and schizophrenia. NRx is additionally the founder and majority owner of HOPE Therapeutics, Inc. (HOPE), a medical services company that offers interventional psychiatry care to patients with treatment-resistant depression and PTSD with a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy. All of our current drug development activities are focused on drugs that enhance neuroplasticity by modulating the N-methyl-D-aspartate (NMDA) receptor in the brain and nervous system, a neurochemical pathway that has been disclosed in detail in our annual filings. The Company has three lead drug candidates – NRX-100, a preservative-free formulation of ketamine for intravenous infusion, a generic preservative-free formulation of ketamine (KETAFREE™), and NRX-101, an oral fixed dose combination of D-cycloserine (DCS) and lurasidone. KETAFREE™, NRX-100 and NRX-101 are in the process of submission for Food and Drug Administration (FDA) approval as follows:

Revenue and profit, by fiscal year.

More on NRXP.

• NRX Pharmaceuticals, Inc. summary
• NRX Pharmaceuticals, Inc. financial statements
• NRX Pharmaceuticals, Inc. key metrics
• NRX Pharmaceuticals, Inc. health scores and style box
• NRX Pharmaceuticals, Inc. earnings
• NRX Pharmaceuticals, Inc. dividends
• NRX Pharmaceuticals, Inc. valuation
• NRX Pharmaceuticals, Inc. ownership and insiders
• NRX Pharmaceuticals, Inc. peers

Figures from NRX Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.